Vasundhara Rasy.

Who are the top shareholders of the Vasundhara Rasy.?

The top shareholder of Vasundhara Rasy is P & J Cretechem Private Limited, holding 61.98%, followed by Garg Leasing And Finance Private Limited at 3.55%, while individual investors own 30.05%. There are no mutual funds or foreign institutional investors in the company.

The top shareholders of Vasundhara Rasy include P & J Cretechem Private Limited, which holds the largest stake at 61.98%. The highest public shareholder is Garg Leasing And Finance Private Limited, with a holding of 3.55%. Additionally, individual investors collectively own 30.05% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Vasundhara Rasy.

how big is Vasundhara Rasy.?

As of Jun 06, Vasundhara Rasayans Ltd has a market capitalization of 66.00 Cr, classifying it as a Micro Cap company, with recent net sales of 33.99 Cr and a net profit of 4.23 Cr. The latest balance sheet shows shareholder's funds of 31.94 Cr and total assets of 37.30 Cr.

Market Cap: As of Jun 06, Vasundhara Rasayans Ltd has a market capitalization of 66.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported Net Sales of 33.99 Cr and a Net Profit of 4.23 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period, which is Mar'24, shows Shareholder's Funds of 31.94 Cr and Total Assets of 37.30 Cr.

What does Vasundhara Rasy. do?

Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids therapeutic category Active Pharmaceutical Ingredients in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 8 Cr and a market cap of Rs 66 Cr.

Overview: <BR>Vasundhara Rasayans Ltd is a leading manufacturer and exporter of Antacids therapeutic category Active Pharmaceutical Ingredients, operating in the Pharmaceuticals & Biotechnology industry within the Micro Cap market segment.<BR><BR>History: <BR>Vasundhara Rasayans Ltd was incorporated in March 1987 and commenced operations in 1990 with an Antacid API facility. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 66 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.98% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 11.90% <BR>Price to Book: 1.82<BR><BR>Contact Details: <BR>Address: Shed No 42 Phase II IDA, Mallapur Hyderabad Telangana : 500076 <BR>Tel: 91-40-23437617/23437623 <BR>Email: info@vrlindia.in <BR>Website: http://www.vasundhararasayans.in

Has Vasundhara Rasy. declared dividend?

Vasundhara Rasayans Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 23, 2024. While the stock has shown strong long-term gains, recent performance reflects negative returns in the short term, and the dividend yield is relatively low at 0.98%.

Vasundhara Rasayans Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.98%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -27.93%, with a dividend return of 0%, resulting in a total return of -27.93%.<BR><BR>Over the past year, the price return was -7.7%, the dividend return was 0.87%, leading to a total return of -6.83%.<BR><BR>In the 2-year period, the price return was 30.53%, the dividend return was 2.57%, culminating in a total return of 33.1%.<BR><BR>During the last 3 years, the price return was 77.1%, with a dividend return of 4.75%, resulting in a total return of 81.85%.<BR><BR>For the 4-year period, the price return was 112.13%, the dividend return was 5.39%, which led to a total return of 117.52%.<BR><BR>In the 5-year span, the price return was 479.66%, with a dividend return of 16.81%, resulting in a total return of 496.47%.<BR><BR>Overall, while Vasundhara Rasayans Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant gains over longer periods but negative returns in the short term. The dividend yield is relatively low, suggesting that while dividends are being paid, the stock may not be performing strongly in the short run.

Who are the peers of the Vasundhara Rasy.?

Vasundhara Rasy.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Vivo Bio Tech, Roopa Industries, Medi Caps, and Dipna Pharmachem. Its 1-year return is -9.07%, lower than Vivo Bio Tech's -5.81%, with average management risk and good capital structure.

Peers: The peers of Vasundhara Rasy. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Vivo Bio Tech, Roopa Industries, Medi Caps, and Dipna Pharmachem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vivo Bio Tech, Vasundhara Rasy., Medi Caps, and JFL Life. Below Average management risk is noted at Roopa Industries, and Dipna Pharmachem does not qualify. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Vivo Bio Tech, Vasundhara Rasy., Medi Caps, and the rest. Good growth is noted at Roopa Industries, while Dipna Pharmachem does not qualify. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good at Torrent Pharma and Vasundhara Rasy., while Average is found at Vivo Bio Tech and JFL Life, and Below Average at Roopa Industries and Medi Caps.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Vivo Bio Tech at -5.81%. Vasundhara Rasy.'s 1-year return is -9.07%, which is lower than Vivo Bio Tech's. Additionally, the six-month return is negative for Vasundhara Rasy., Vivo Bio Tech, Medi Caps, and Torrent Pharma.

What is the technical trend for Vasundhara Rasy.?

As of May 23, 2025, Vasundhara Rasy's technical trend has shifted to a moderate bearish stance, supported by bearish signals from key indicators like the MACD, Bollinger Bands, and moving averages, along with significant underperformance compared to the Sensex.

As of 23 May 2025, the technical trend for Vasundhara Rasy has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing bearish signals. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory reflects a mildly bearish stance on the weekly and monthly time frames. The stock has underperformed significantly compared to the Sensex over various periods, particularly year-to-date and over the past year.

Who are in the management team of Vasundhara Rasy.?

As of March 2022, the management team of Vasundhara Rasy includes Sunil Jain Kumar, Sanjoy Kumar Jain, Rajesh Pokerna, Seema Jain, Manish Kumar Jain as executive directors, along with independent directors Pradeep Kumar Jain, Pravichandra Majumdar Popatlal, Rajiv Kakodkar, Manish Jain, and Ashish Kedia. This diverse team oversees the company's governance and strategic direction.

As of March 2022, the management team of Vasundhara Rasy includes the following individuals:<BR><BR>1. Sunil Jain Kumar - Executive Director / Whole Time Director<BR>2. Sanjoy Kumar Jain - Executive Director & Whole Time Director<BR>3. Rajesh Pokerna - Executive Director & Managing Director<BR>4. Seema Jain - Executive Director & Whole Time Director<BR>5. Pradeep Kumar Jain - Independent Non-Executive Director<BR>6. Pravichandra Majumdar Popatlal - Independent Non-Executive Director<BR>7. Rajiv Kakodkar - Independent Non-Executive Director<BR>8. Manish Jain - Independent Director<BR>9. Ashish Kedia - Independent Director<BR>10. Manish Kumar Jain - Whole-time Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

Are Vasundhara Rasy. latest results good or bad?

The latest results for Vasundhara Rasayans are concerning, with a 65.89% decline in Profit After Tax and an 11% decrease in net sales, leading to a 'Strong Sell' rating from MarketsMOJO. Overall, the company is facing significant financial challenges.

The latest results for Vasundhara Rasayans indicate a challenging period for the company. The Profit After Tax (PAT) for the last six months is Rs 1.02 crore, which is a significant decline of 65.89% year-on-year. Additionally, net sales for the quarter reached Rs 7.56 crore, reflecting an 11% decrease compared to the average of Rs 8.50 crore over the previous four quarters. This marks the lowest quarterly sales the company has recorded in the past five quarters.<BR><BR>While there has been a slight improvement in the financial score, moving from -14 to -9 over the last three months, the overall performance remains negative. As a result, the company has received a 'Strong Sell' rating from MarketsMOJO, indicating ongoing challenges ahead. Overall, the financial results suggest that Vasundhara Rasayans is currently facing significant difficulties.

How has been the historical performance of Vasundhara Rasy.?

Vasundhara Rasy has experienced fluctuating net sales and profits, peaking at 37.94 Cr in Mar'23 but declining to 33.99 Cr by Mar'25, alongside a decrease in profitability and negative cash flow trends. Despite an increase in total assets and liabilities, the company's operating profit margin and overall profitability have faced significant challenges.

Answer:<BR>The historical performance of Vasundhara Rasy shows a fluctuating trend in net sales and profits over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Vasundhara Rasy's net sales peaked at 37.94 Cr in Mar'23 but fell to 33.99 Cr by Mar'25. The total operating income followed a similar trend, decreasing from 37.94 Cr in Mar'23 to 33.99 Cr in Mar'25. The raw material costs have remained relatively stable, with a slight increase from 15.53 Cr in Mar'24 to 15.63 Cr in Mar'25. Operating profit (PBDIT) also declined from 8.33 Cr in Mar'24 to 6.40 Cr in Mar'25, reflecting a decrease in operating profit margin from 17.26% to 11.92%. Profit before tax decreased from 7.90 Cr in Mar'24 to 5.77 Cr in Mar'25, while profit after tax dropped from 5.86 Cr to 4.25 Cr in the same period. The company's total assets increased from 37.30 Cr in Mar'24 to 43.07 Cr in Mar'25, alongside a rise in total liabilities from 37.30 Cr to 43.07 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 5.00 Cr in Mar'25 compared to an inflow of 6.00 Cr in Mar'24. Overall, while Vasundhara Rasy has seen growth in total assets, its profitability and cash flow have faced challenges in recent years.

Is Vasundhara Rasy. overvalued or undervalued?

As of December 4, 2025, Vasundhara Rasy. is considered overvalued with a valuation grade of "expensive," a PE Ratio of 13.42, and a year-to-date return of -35.36%, significantly lagging behind its peers and the Sensex.

As of 4 December 2025, the valuation grade for Vasundhara Rasy. has moved from very expensive to expensive, indicating a shift in perception regarding its market valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 13.42, an EV to EBITDA of 14.79, and a ROE of 12.74%. <BR><BR>In comparison to peers, Vasundhara Rasy.'s PE Ratio is significantly lower than Solar Industries, which has a PE of 88.66, and Gujarat Fluoroch at 54.14. While Vasundhara Rasy. shows a PEG Ratio of 0.00, indicating no growth expectations, its current valuation does not align favorably with its peers in the Pharmaceuticals & Biotechnology sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -35.36% compared to the Sensex's 9.12%, further reinforcing the overvaluation narrative.

Should I buy, sell or hold Vasundhara Rasy.?

When is the next results date for Vasundhara Rasayans Ltd?

The next results date for Vasundhara Rasayans Ltd is 10 February 2026.

The next results date for Vasundhara Rasayans Ltd is scheduled for 10 February 2026.

Why is Vasundhara Rasayans Ltd falling/rising?

As of 07-Feb, Vasundhara Rasayans Ltd's stock price is 151.30, down 1.08%, despite a recent 11.51% gain over four days. The stock has underperformed the Sensex over the past year, with a 48.71% decline, and shows declining investor interest, reflected in a 33.04% drop in delivery volume.

As of 07-Feb, Vasundhara Rasayans Ltd's stock price is currently at 151.30, reflecting a decrease of 1.65 or 1.08%. Despite this decline, the stock has shown some positive performance recently, having gained 11.51% over the last four days. Today, it opened with a gain of 4.61% and reached an intraday high of Rs 165, which indicates strong initial interest.<BR><BR>However, the overall trend shows that the stock has been underperforming compared to the benchmark Sensex, particularly over longer periods. Over the past year, the stock has fallen by 48.71%, while the Sensex has increased by 7.07%. Additionally, the stock's year-to-date performance shows a decline of 11.05%, compared to a smaller drop of 1.92% in the Sensex.<BR><BR>Investor participation appears to be declining, as evidenced by a significant drop in delivery volume, which fell by 33.04% against the 5-day average. This suggests that while there may be short-term gains, the overall sentiment towards the stock remains cautious, contributing to the current price decline. The stock is trading above its 5-day and 20-day moving averages, but below its longer-term moving averages, indicating mixed signals regarding its performance trajectory.

Which are the latest news on Vasundhara Rasy.?